PIPELINE
Our Portfolio
We work on the best targets for patients
We have an exciting pipeline of novel, differentiated small molecules against membrane proteins and intracellular complexes – Solute Carriers, GPCRs, Inflammasome – with a focus on immunological and orphan diseases. We select targets with low translation risk through genetic association, pathway linked patient selection or immune signature stratification.

Click Target For More Info

Target Indication Discovery Preclinical Phase 1
MC2Orphan endocrine disorders
SLC15A4Lupus and other IFN-opathies
GPR65Inflammatory bowel disease
GasderminBroad immunology
cGASBroad immunology
MC2
Insurmountable ACTH antagonism for a best-in-class profile in rare endocrine disorders.
SLC15A4
First-in-class solute carrier inhibitor against a highly validated target in Lupus and other IFN-opathies
GPR65
First-in-class molecules driving novel anti-inflammatory biology in Inflammatory Bowel Disease.
Gasdermin
First-in-class Gasdermin D inhibitors – a pipeline in a product.
cGAS
Best-in-class cGAS inhibitor

PIPELINE

Need more information about our pipeline?

Contact Us